Treatments · the misinformation we still meet
Menopausal hormone therapy (MHT), often called HRT, still comes with a lot of questions. More than 20 years after the Women's Health Initiative press conference, the misinformation it set off is still keeping women off treatment that would have helped them. Here's what the evidence actually says, written without the medical defensiveness or the activist overcorrection.
Why this page exists
MHT is one of the most studied medications in modern medicine, and one of the most persistently misunderstood. A generation of women were taken off it in 2002 on the strength of a press conference, and a generation of doctors was trained in its shadow. The picture has shifted considerably since, but the public conversation hasn't fully caught up. This isn't a sales pitch for HRT, it's the honest answer to the eight things you'll most likely hear from a friend, a forum, or sometimes a doctor who hasn't updated since the early 2000s.
Myth 01
Combined MHT increases breast cancer risk; the size depends on duration, regimen and your baseline risk.
NICE's current guidance says breast cancer risk with combined HRT rises with duration and can persist for at least 10 years after stopping. Estrogen-only HRT carries very little or no increase, but is usually only appropriate after hysterectomy. The WHI estrogen-only trial found lower incidence and mortality with one specific formulation; this doesn't establish MHT as cancer prevention. A 2024 Norwegian cohort still found breast cancer associations with systemic oral and transdermal treatment. Some observational studies suggest differences between progestogens, but NICE says evidence is insufficient to establish lower breast cancer risk with micronized progesterone or dydrogesterone. The BMJ 2020 study didn't evaluate micronized progesterone. A patch can lower clot risk without removing breast cancer risk. Your own baseline risk, symptoms and treatment preferences all belong in the conversation.
Myth 02
WHI tested one specific combination in mostly older women and found a much narrower problem than the press conference said.
The WHI study used conjugated equine estrogen plus medroxyprogesterone acetate (a synthetic progestin), in women whose average age was 63 and whose average distance from menopause was 12 years. That isn't most of the women asking about HRT today. When the same data is re-analyzed by age at starting — a post-hoc subgroup analysis, so read it as suggestive rather than settled — the women who began HRT within ten years of menopause did not show the cardiovascular harm the headline claimed, and some outcomes (mortality, hip fracture) appeared to favour treatment. WHI is not a 'never start MHT' study. It's a 'don't start HRT for the first time at 65 to prevent heart disease' study, which is what the current guidelines actually say.
Myth 03
Body-identical (regulated estradiol and micronized progesterone) is a real, measurable thing. 'Bioidentical compounded' is the marketing term to be careful of.
Regulated body-identical MHT (transdermal estradiol, oral micronized progesterone) is chemically identical to the hormones the ovary makes, available on prescription, and dose-tested through manufacturing standards. Compounded 'bioidentical' hormones, mixed by a private pharmacy from a private clinic's prescription, are also chemically identical but aren't dose-tested batch by batch, aren't licensed, and are usually significantly more expensive. The two are often deliberately conflated in marketing. The honest position: ask for the regulated body-identical option first; the compounded version exists but the case for it over the licensed product is weak in most situations.
Myth 04
'Natural' isn't a regulatory category. Plant-derived estrogens still carry estrogenic risk; herbs aren't tested the way drugs are.
Soy isoflavones, black cohosh, red clover and dong quai all act on estrogen pathways to varying degrees, with varying evidence behind them. Some have modest signals for hot flashes; most have small effects at best. None of them are 'risk-free because they're plants'. Black cohosh in particular has been linked to rare cases of liver injury. Compounded creams labelled 'natural progesterone' are still pharmacological doses of progesterone with the same effects as the prescription version. The framing that should sound the alarm is 'this is natural so it must be safe', that's not how pharmacology works in either direction.
Myth 05
There's no fixed time limit. The trade-off should be reviewed periodically, not auto-stopped on a deadline.
There isn't a fixed stopping deadline for everyone. The Menopause Society's 2022 statement advises against routinely stopping at 65. The 2025 European Society of Endocrinology guideline recommends an individual approach to continuation over 60, considering symptoms, changing risks, bone health and preferences. NICE recommends discussing duration from the outset and reviewing benefits and risks at every review. Starting later is a separate decision from continuing treatment already in use. A 2024 Medicare study adds observational evidence that outcomes differ by type, route and dose; it can't prove HRT extends life. Ongoing symptoms or bone concerns can justify longer use after review, but HRT shouldn't be prescribed to prevent heart disease or dementia.
Myth 06
Severity is one factor; the timing window, your bone and cardiovascular risk, and your quality of life are all part of the picture.
The 'wait until you can't function' framing misses two things. First, the timing window: starting HRT in early menopause (within ten years of the final period, or before age 60) appears to carry a more favourable risk-benefit profile than starting it later. Second, HRT isn't only about flushes; it has measurable effects on bone density, genitourinary syndrome of menopause (GSM), sleep architecture and, in some studies, cardiovascular risk markers. If your symptoms are real and affecting your life, even at a 4-out-of-10 not a 9-out-of-10, that's a legitimate reason to discuss treatment, as long as your doctor has first ruled out anything that would make HRT unsuitable, like a clotting disorder, active liver disease, or a hormone-sensitive cancer history. Suffering more first isn't a clinical requirement.
Myth 07
Some symptoms can rebound on stopping; tapering helps. But you've also bought yourself the years on it, which counts.
Some people find vasomotor symptoms return when they come off MHT, particularly if they stop abruptly. A slow taper over several months reduces the rebound for most. But this 'you'll just have to do it eventually' framing assumes the years on HRT don't count, which they do. Better sleep, better mood, lower fracture risk, better sexual function and, for many, better cognition during your 50s and 60s aren't a postponement. They're the years themselves. If symptoms recur on stopping and they're bad enough to need treatment again, restarting is reasonable in most cases.
Myth 08
Low-dose vaginal estrogen has much less systemic absorption. After breast cancer, it needs its own treatment discussion.
Local vaginal estrogen treats vaginal and urinary symptoms, rather than hot flashes. NICE recommends considering it after breast cancer when non-hormonal moisturizers and lubricants haven't helped enough. A 2025 AJOG review found no overall recurrence increase in observational studies; a January 2024 JAMA Oncology study found no higher early breast cancer-specific mortality, but didn't assess recurrence. These findings don't prove it's risk-free. Recurrence risk remains uncertain after estrogen receptor-positive cancer, particularly with aromatase inhibitors, so involve your breast cancer specialist before starting. Regulatory label changes are a separate matter and don't establish systemic MHT safety after hormone-sensitive cancer.
Where to next
The honest numbers
Breast, endometrial, ovarian and beyond — absolute numbers by formulation and duration, not headlines.
Cancer risk, plainlyBack to the menu
MHT, non-hormonal Rx, vaginal therapies, bone meds, the menu, in plain language.
TreatmentsFind a doctor
A menopause-literate doctor or specialist will recognize everything on this page. Most GPs won't.
PractitionersGo to source
WHI re-analyzes, KEEPS, ELITE, the timing-hypothesis trials, and the recent guideline updates.
ResearchEvidence checked October 2026.
Continuation after 60 should be individualized, considering symptoms, changing risks, bone health and preferences.
Lumsden et al.; recommendation R 3.1
A clinical guideline, not a new trial. It recommends a targeted approach to continuing MHT over 60, rather than an automatic age-based stop. Supported by the European Society of Endocrinology. Full text is also available in Imperial College London's research archive.
Read the sourceReview the benefits and risks of continuing MHT at every review.
Guideline updated 15 April 2026. Duration recommendation 1.4.3 was updated in 2024; review at 3 months, then annually (1.9.2). A newer guideline date doesn't mean every recommendation is new.
Read the sourceAfter 65, associations differ by hormone type, route and dose.
Baik, Baye and McDonald; 10 million Medicare women, 2007 to 2020
Prescription and claims study, not a randomized trial. Estrogen-only use was associated with lower breast cancer incidence; combined therapy with higher incidence. Prior treatment history and unmeasured health differences limit interpretation. It doesn't prove MHT prevents cancer or extends life. NIH-funded; no financial conflicts reported.
Read the sourceFor people who start hormone therapy before age 60 or within 10 years of menopause, the benefits generally outweigh the risks.
The 2022 hormone therapy position statement of The North American Menopause Society
The statement behind the 'timing window' idea: when you start matters more than age alone. The same statement advises against automatically stopping at 65. Starting or continuing after 60 is still an individual decision to weigh with your doctor or specialist, not an automatic yes.
Read the sourceA newer Norwegian cohort still found breast cancer associations with systemic MHT.
Støer et al.; 1,275,783 women aged 45 and over
Risk varied by formulation; oral estrogen with daily progestin had the highest association. Transdermal systemic treatment wasn't free of a breast cancer association. Observational, not proof of causation. The August 2025 correction changed detection-mode data, not the overall conclusions; this link shows the corrected article. Funding: none reported.
Read the sourcePooled observational studies found no overall increase in recurrence with vaginal estrogen.
Beste et al.; 8 observational studies, 24,060 patients in the recurrence analysis
Published online November 2024, in the March 2025 issue. The review pooled unadjusted estimates, so differences between users and non-users can influence results. It doesn't prove a protective effect or settle safety during aromatase inhibitor treatment.
Read the sourceVaginal estrogen wasn't associated with higher early breast cancer-specific mortality.
McVicker et al.; 49,237 women in Scotland and Wales
Published online November 2023, in the January 2024 issue. This study assessed deaths, not recurrence; those are different outcomes. Observational evidence can't establish causation. Funded by Cancer Research UK.
Read the sourceAfter breast cancer, consider vaginal estrogen when non-hormonal care hasn't helped enough.
Survivorship recommendations were updated in 2024. Recurrence risk remains uncertain after estrogen receptor-positive cancer. People on aromatase inhibitors should identify options with a breast cancer specialist. Low-dose local treatment and systemic MHT are separate decisions.
Read the sourceReferences & further reading
Most of what circulates about MHT and breast cancer traces back to a handful of studies. Here are the primary sources, not the headlines.
Primary sources
Dr. Jen Gunter, Obstetrics & Gynecology 2025 (expert commentary)
Why so much popular menopause content online isn't evidence-based, and how doctors can answer the questions it raises. Full text is for subscribers.
VisitManson et al., JAMA 2017 (WHI 18-year follow-up)
The long-term WHI follow-up that complicated the original 2002 headline. No increase in all-cause mortality across 18 years.
VisitJAMA Internal Medicine 2026 (WHI secondary analysis, n=27,347)
The first US analysis to look at cardiovascular outcomes from HT specifically in women with hot flashes and night sweats. HT didn't raise CV risk in younger symptomatic women and appeared protective; risk concentrated in women aged 70 and older.
VisitNICE (UK)
The UK guideline that recommends transdermal estradiol as the default for most women, and quantifies breast-cancer risk in plain absolute numbers.
VisitThe Menopause Society (NAMS)
The North American consensus on who MHT is appropriate for, when to start, and how long to stay on it.
VisitBritish Menopause Society
The short reference doctors use day-to-day. Useful if you want to know what your GP is meant to know.
VisitGravelsins, Perović, Galea et al., Science 2026 (narrative review)
A review, not a new trial. Its strongest points: hormone therapy isn't one thing (type, route, dose and timing all change the picture), and menopause research has been underfunded for decades. Some figures in the paper have been publicly questioned for overstating what the randomized trials found, so lean on the trials above for numbers.
Visit